Scarica l'app Stockscreener
3.39
2.87%
-0.10
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - AOL.com
Niagen Bioscience files prospectus to offer common stock up to $50M - scanx.trade
Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com - Investing.com South Africa
Canaccord reiterates Niagen Bioscience stock rating on drug launch By Investing.com - Investing.com Canada
Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt - Law360
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital - MarketBeat
Niagen Bioscience unveils NB-4168 for ataxia telangiectasia - BioWorld News
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 - Business Wire
Form 4 Niagen Bioscience Inc For: 8 July By Investing.com - Investing.com Nigeria
Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan - Stock Titan
Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases - marketscreener.com
Niagen Bioscience launches drug candidate for rare disease - Investing.com
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases - Business Wire
Enterprise value to EBIT forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Freedom Capital Markets Initiates Niagen Bioscience(NAGE.US) With Buy Rating, Announces Target Price $9 - Moomoo
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com - Investing.com Nigeria
Freedom Broker initiates Niagen Bioscience stock coverage with buy rating - Investing.com
Implied Volatility Surging for Niagen Bioscience Stock Options - Zacks Investment Research
NAGENiagen Bioscience Inc Options - Finviz
H.C. Wainwright reiterates Niagen Bioscience stock rating on patent ruling By Investing.com - Investing.com India
Form S-3 Niagen Bioscience Inc For: 29 June By Investing.com - Investing.com Australia
Form 4 Niagen Bioscience Inc For: 26 June By Investing.com - Investing.com South Africa
Niagen Bioscience (NAGE) director receives 31,746 stock options at $3.45 strike - Stock Titan
Niagen Bioscience (NAGE) director awarded options for 31,746 shares at $3.45 strike - Stock Titan
Director at Niagen Bioscience (NAGE) receives 31,746 stock options award - Stock Titan
Niagen Bioscience (NAGE) director granted 31,746 stock options at $3.45 - Stock Titan
Niagen Bioscience (NAGE) director receives 31,746-share stock option grant at $3.45 - Stock Titan
Director Steven D. Rubin receives 31,746 Niagen Bioscience (NAGE) stock options - Stock Titan
Niagen Bioscience (NAGE) director receives grant of 31,746 stock options at $3.45 - Stock Titan
Niagen Bioscience Inc (NAGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
NAGE Forecast — Price Target — Prediction for 2027 - TradingView
Niagen Bioscience, Inc. Actuals & Estimates (NASDAQ:NAGE) - TradingView
Enterprise value to revenue forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Price to sales forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Enterprise value to EBITDA forward of Niagen Bioscience, Inc. – NASDAQ:NAGE - TradingView
Niagen Bioscience Inc (NAGE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Niagen Bioscience Inc (NAGE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Niagen Bioscience Renames Research Program to Advance NAD Cellular Health Studies - sekbernews.id
Niagen Bioscience Renames Research Program to Focus on NAD+ ApplicationsGuidance vs Actual - dars.gov.et
Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications - Insider Monkey
Niagen Bioscience Inc (NAGE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Niagen Bioscience Inc (NAGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Niagen Bioscience Inc (NAGE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Niagen Bioscience Inc (NAGE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Niagen Bioscience Inc (NAGE) Institutional Confidence - TradingKey
Niagen Bioscience And 2 Other Promising Penny Stocks To Watch - simplywall.st
Niagen Bioscience (NAGE) Slips 1.14% as Stock Tests Key Support at $3.30OBV Breakout - dars.gov.et
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):